NCT03223337View on ClinicalTrials.gov

Daprodustat Hepatic Impairment Study

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 24, 2017

Primary Completion Date

August 20, 2018

Study Completion Date

August 20, 2018

Conditions
Anaemia
Interventions
DRUG

Daprodustat (GSK1278863)

Daprodustat (GSK1278863) 6 mg tablet will be given to all subjects as a single dose via oral route. Daprodustat (GSK1278863) is a 9.0 millimeter (mm) round, compound radius, white film coated tablet.

Trial Locations (2)

32809

GSK Investigational Site, Orlando

33136

GSK Investigational Site, Miami

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03223337 - Daprodustat Hepatic Impairment Study | Biotech Hunter | Biotech Hunter